Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22833585 | 0.91 | HCRTR1 (0.40) | TP53MDM2HCRTR2HCRTR1 | |
| SCHEMBL9122938 | 0.85 | ABL1 (0.49) | KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL22854675 | 0.81 | TP53 (0.38) | TP53MDM2HCRTR2HCRTR1P2RX7 | |
| SCHEMBL9127051 | 0.80 | TSHR (0.39) | HCRTR2HCRTR1P2RX7 | |
| SCHEMBL9831208 | 0.78 | TP53 (0.45) | TP53MDM2KDM4ESMN1; SMN2BRD4 | |
| SCHEMBL10881007 | 0.75 | TP53 (0.44) | TP53MDM2P2RX7BRD4KMT2A | |
| SCHEMBL10881010 | 0.75 | TP53 (0.44) | TP53MDM2P2RX7BRD4KMT2A | |
| SCHEMBL26744988 | 0.75 | TP53 (0.44) | TP53MDM2KDM4ESMN1; SMN2P2RX7 | |
| SCHEMBL26744929 | 0.75 | TP53 (0.44) | TP53MDM2KDM4ESMN1; SMN2P2RX7 | |
| SCHEMBL22833713 | 0.74 | TP53 (0.46) | TP53MDM2KDM4ESMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| CN-115594680-A | TEAD inhibitor | 武汉人福创新药物研发中心有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | TP53 336/4885MDM2 1075/4885KDM4E 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.